Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia. It plays an essential function in calcium homeostasis and bone metabolism.
- Mechanism
- Curator reviewed · 1 reference
In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys' capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D.
- Primary indication
- Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.Curator reviewed · 11 structured indications
- Formula / weight
- C27H44O2 · 400.6371 g/mol (avg)
- First approval
- Canada, 1999
- Brand names
Resolves to
OFHCOWSQAMBJIW-AVJTYSNKSA-NSMILESCC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Alfacalcidol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account